Anal Cancer
EGFR is overexpressed in the majority of patients with squamous cell anal carcinoma4,5 and is likely linked to tumor-genesis and progression in anal cancer.5
Breast Cancer
EGFR is overexpressed in up to 14% of breast tumors, with a higher incidence in hereditary breast cancer.7 In patients who have TNBC, overexpression of EGFR is associated with increased metastasis and poor prognosis.7,2
Cervical Cancer
Up to 91% of patients with advanced cervical cancers overexpress EGFR. Significantly higher EGFR overexpression is reported in tumor size >4 cm and ulcerative lesions.8
Colorectal Cancer
EGFR is overexpressed in approximately 60%-80% of colorectal tumors. It is associated with poor prognosis.9
Endometrial Cancer
EGFR overexpression in endometrial cancer is linked to a decrease in disease-free and overall survival.10 It is overexpressed in up to 67% of cases.11
Esophageal Cancer
EGFR expression in esophageal squamous cell carcinoma and esophageal and esophagogastric junction adenocarcinoma is associated with worse prognosis and may be used to predict outcomes.12,13
Gastric Cancer
Overexpression of EGFR in gastric tumors is reported in 27%-64% of patients but its prognostic value is unknown.14
Glioblastoma Cancer
Primary glioblastomas have a higher incidence of EGFR gene amplification (40%) and EGFR overexpression (>60%) compared to secondary glioblastoma (8% and 10%, respectively). EGFR amplification becomes more common as a patient gets older.15
Head and Neck Cancer
The majority of people with squamous cell carcinoma of the head and neck overexpress EGFR,16 and is tied to poor prognosis.17
Lung Cancer
EGFR is expressed in >60% of Non–Small-cell lung carcinomas18 and is associated with reduced survival, lymph node metastasis, and poor chemosensitivity.19
